Skip to main content

Table 6 The interaction analysis between risk variants and clinicopathological parameters

From: Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer

SNPs

Variable

iDFS

DDFS

BCSS

OS

Adjusted HRa

P value

Adjusted HRa

P value

Adjusted HRa

P value

Adjusted HRa

P value

rs4415084

Age at diagnosis

        

 CC

 ≤ 35

1 (reference)

 

1 (reference)

 

1 (reference)

 

1 (reference)

 

 CC

 > 35

1.113 (0.739–1.676)

0.609

1.270 (0.814–1.983)

0.292

1.366 (0.829–2.249)

0.221

1.346 (0.827–2.189)

0.232

 CT

 ≤ 35

1.317 (0.797–2.176)

0.282

1.421 (0.829–2.438)

0.202

1.358 (0.733–2.516)

0.331

1.271 (0.692–2.336)

0.440

 CT

 > 35

1.090 (0.734–1.619)

0.669

1.246 (0.810–1.917)

0.316

1.373 (0.847–2.229)

0.198

1.340 (0.835–2.148)

0.225

 TT

 ≤ 35

2.013 (1.161–3.488)

0.013

2.427 (1.357–4.339)

0.003

2.505 (1.310–4.788)

0.005

2.497 (1.328–4.693)

0.004

 TT

 > 35

1.180 (0.767–1.815)

0.452

1.332 (0.836–2.124)

0.228

1.461 (0.868–2.460)

0.153

1.378 (0.826–2.298)

0.219

P for multiplicative interaction

 

0.045

 

0.013

 

0.025

 

0.018

 rs3803662

 Grade

        

  GG

  I + II

1 (reference)

 

1 (reference)

 

1 (reference)

 

1 (reference)

 

  GG

  III

1.858 (1.400–2.466)

1.8E−5

1.877 (1.394–2.527)

3.3E−5

2.134 (1.543–2.952)

4.6E−6

2.018 (1.469–2.773)

1.5E−5

  GA

  I + II

1.031 (0.814–1.306)

0.801

1.106 (0.864–1.416)

0.425

1.139 (0.862–1.505)

0.361

1.054 (0.801–1.385)

0.709

  GA

  III

1.043 (0.746–1.459)

0.804

1.014 (0.711–1.446)

0.939

0.979 (0.655–1.462)

0.917

0.946 (0.639–1.403)

0.784

  AA

  I + II

0.994 (0.684–1.443)

0.973

1.081 (0.735–1.592)

0.691

1.246 (0.820–1.893)

0.303

1.195 (0.793–1.800)

0.394

  AA

  III

1.085 (0.582–2.023)

0.798

1.245 (0.665–2.331)

0.493

1.043 (0.501–2.169)

0.911

0.983 (0.474–2.041)

0.964

P for multiplicative interaction

 

0.011

 

0.001

 

4.7E−4

 

9.9E−4

  1. aHR hazard risk, CI confidence interval; adjusted for age at diagnosis, tumor size, Lymph node involvement, grade, hormone receptor status and HER2 status, except for the interaction factor